Dr Miguel Baretto-Sanz
Our company Phages4A (Phages For All) has developed a technology based on artificial intelligence, able to predict in an in-silico way (via computer simulation) the phages that can specifically infect and kill a bacteria. Our technology harnesses the genome of phages and bacteria and relies on bacterial-phage interaction databases to train artificial intelligence algorithms. The models thus developed make it possible to select the phages that can specifically infect and kill a given bacteria. Our predictions help to create custom bacteriophage cocktails to treat patients with bacterial infections.
More specifically we aim to:
- Help companies working on phage therapy to speed their processes to identify host range
- Provide to hospitals and clinics with software tools to accelerate the treatment of patients suffering of diseases related antibiotic-resistant bacteria.
- Bring our products and services to other industries including but not limited to food safety, aquaculture, veterinary, and agriculture where bacteria resistant to antibiotics is an important issue.
Dr Gregory Resch
Dr Aleksandra Petrovic Fabijan
Dr Pieter-Jan Ceyssens
Eric Pelfrene
I am employed at the European Medicines Agency (EMA), with responsibilities mainly focused on regulatory guidance pertaining new antibacterial products and medicines for use against WHO target infections, such as malaria. At EMA we are looking at the lifecycle of each product, through registration and post-authorisation phase, ensuring safe and effective medicines with certified quality to be available for patients throughout the European Union. The Agency also plays a role in supporting research and innovation in the pharmaceutical sector and promotes innovation and development of new medicines by European micro- small- and medium-sized-enterprises.
